Brad S. Kahl, MD

Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the mantle cell lymphoma treatment paradigm.

Brad Kahl, MD, discusses the ongoing unmet needs in the treatment of mantle cell lymphoma.

Brad S. Kahl, MD, explains the importance of identifying less intensive induction regimens for older patients with mantle cell lymphoma.

Brad S. Kahl, MD, details the outcomes of bortezomib plus bendamustine/rituximab in patients with mantle cell lymphoma.

Brad S. Kahl, MD, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma.

Brad S. Kahl, MD, discusses current best practices for the treatment of older patients with mantle cell lymphoma, as well as where the treatment paradigm might lead in the future.

Brad S. Kahl, MD, discusses the potential utility of frontline CAR T-cell therapy in mantle cell lymphoma.

Brad S. Kahl, MD, discusses a potential limitation of frontline combination strategies with BTK inhibitors in mantle cell lymphoma.

Brad S. Kahl, MD, discusses patient selection for intensive vs non-intensive treatment strategies in mantle cell lymphoma.

Brad S. Kahl, MD, discusses the potential utility of BTK inhibitor–based combinations in the frontline setting of mantle cell lymphoma.

Brad S. Kahl, MD, discusses the differences between mechanisms of action of PI3K inhibitors in follicular lymphoma.

Brad S. Kahl, MD, discusses selecting between PI3K inhibitors in follicular lymphoma.

Brad S. Kahl, MD, discusses remaining challenges with CAR T-cell therapy in diffuse large B-cell lymphoma.

Brad S. Kahl, MD, discusses findings from the phase 2 L-MIND study in diffuse large B-cell lymphoma.

Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.